MedTrace Logo

Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer

NCT00126165 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2012-01-19

No results posted yet for this study

Summary

This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.

Conditions

Interventions

PROCEDURE

radiotherapy

Sponsors & Collaborators

  • Calgary Health Region

    collaborator OTHER

  • Alberta Health services

    lead OTHER

Principal Investigators

  • Jackson Wu · AHS Cancer Control Alberta

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2011-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00126165 on ClinicalTrials.gov